Chronic fatigue syndrome is a complex disease with no specific treatment recommendations

被引：0

作者：

不详

机构：

来源：

Drugs & Therapy Perspectives | 2004年 / 20卷 / 3期

关键词：

Cognitive Behavioural Therapy; Chronic Fatigue Syndrome; Neopterin; Natural Killer Cell Function; Human Herpes Virus Type;

D O I：

10.2165/00042310-200420030-00004

中图分类号：

学科分类号：

摘要：

Chronic fatigue syndrome (CFS) is a medically unexplained disease with an unclear pathogenesis. The development of CFS may involve a relationship between the immune system and the CNS with the possible involvement of a microorganism. The main symptoms of CFS include unexplained fatigue, impairment of neurocognitive functions and sleep quality, and somatic symptoms. No specific treatment for CFS has been identified and, to date, there is insufficient clinical trial evidence to make conclusive treatment recommendations. Cognitive behavioural therapy is established as a method of improving quality of life, and is most effective when used on an individual patient basis. Clinician education and effective management strategies are urgently needed in order to effectively treat patients with CFS. © 2004 Adis Data Information BV. All rights reserved.

引用

页码：9 / 13

页数：4

共 12 条

[1]

Evengard B., Klimas N., Chronic fatigue syndrome: Probable pathogenesis and possible treatment, Drugs, 62, 17, pp. 2433-2446, (2002)

[2]

VA/DoD clinical practice guideline for the management of medically unexplained symptoms: Chronic pain and fatigue, (2001)

[3]

Fukuda K., Straus S., Hickie I., Et al., The chronic fatigue syndrome: A comprehensive approach to its definition and study, Ann. Intern. Med., 121, pp. 953-959, (1994)

[4]

Powell R., Dolan R., Wessely S., Attributions of self-esteem in depression and chronic fatigue syndromes, J. Psychosom. Res., 34, pp. 665-673, (1990)

[5]

Komaroff A.L., Minor" illness symptoms: The magnitude of their burden and of our ignorance, Arch. Intern. Med., 150, pp. 1586-1587, (1990)

[6]

White P.D., Thomas J.M., Amess J., Et al., Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever, Br. J. Psychiatry, 173, pp. 475-481, (1998)

[7]

Cannon J.G., Angel J.B., Abad L.W., Et al., Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome, J. Clin. Immunol., 17, pp. 253-261, (1997)

[8]

Cope H., David A.S., Neuroimaging in chronic fatigue syndrome, J. Neurol. Neurosurg. Psychiatry, 60, pp. 471-473, (1996)

[9]

Johnson S.K., DeLuca J., Fiedler N., Et al., Cognitive functioning of patients with chronic fatigue syndrome, Clin. Infect. Dis., 18, SUPPL. 1, (1994)

[10]

Ax S., Gregg V.H., Jones D., Chronic fatigue syndrome: Sufferer s evaluation of medical support, J. R. Soc. Med., 90, pp. 250-254, (1997)

← 1 2 →